ロード中...
A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of ther...
保存先:
| 出版年: | Pharmacol Res Perspect |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8137807/ https://ncbi.nlm.nih.gov/pubmed/34018344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.792 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|